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Summary
Background Epidemiology data regarding hidradenitis suppurativa (HS) are conflict-
ing and prevalence estimates vary 80-fold, from 005% in a population-based
study to 4%.
Objectives To assess the hypothesis that previous population-based studies under-
estimated true HS prevalence by missing undiagnosed cases.
Methods We performed a population-based observational and case–control study
using the U.K. Clinical Practice Research Datalink (CPRD) linked to hospital epi-
sode statistics data. Physician-diagnosed cases in the CPRD were identified from
specific Read codes. Algorithms identified unrecognized ‘proxy’ cases, with at
least five Read code records for boils in flexural skin sites. Validation of proxy
cases was undertaken with general practitioner (GP) questionnaires to confirm
criteria-diagnosed cases. A case–control study assessed disease associations.
Results On 30 June 2013, 23 353 physician-diagnosed HS cases were documented
in 4 364 308 research-standard records. In total, 68 890 proxy cases were iden-
tified, reduced to 10 146 criteria-diagnosed cases after validation, extrapolated
from 107 completed questionnaires (61% return rate). Overall point prevalence
was 077% [95% confidence interval (CI) 076–078%]. An additional 18 417
cases had a history of one to four flexural skin boils. In physician-diagnosed
cases, odds ratios (ORs) for current smoker and obesity (body mass index
> 30 kg m–2) were 361 (95% CI 344–379) and 329 (95% CI 314–345). HS
was associated with type 2 diabetes, Crohn disease, hyperlipidaemia, acne and
depression, and not associated with ulcerative colitis or polycystic ovary syn-
drome.
Conclusions Contrary to results of previous population-based studies, HS is rela-
tively common, with a U.K. prevalence of 077%, one-third being unrecognized,
criteria-diagnosed cases using the most stringent disease definition. If individuals
with probable cases are included, HS prevalence rises to 119%.
What’s already known about this topic?
• Previous population-based studies suggest that the prevalence of hidradenitis sup-
purativa (HS) may be as low as 005% but existing studies have not quantified
undiagnosed cases.
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What does this study add?
• Analysis of 43 million research-standard records in the U.K. Clinical Practice
Research Datalink demonstrates a HS prevalence of 077% using the most stringent
disease definition [95% confidence interval (CI) 076–078%], one-third being
undiagnosed cases, rising to 119% (95% CI 118–120%) if probable cases are
included.
Hidradenitis suppurativa (HS), also known as acne inversa, is
an inflammatory skin disease producing functional impairment
similar in magnitude to cardiovascular disease, type 2 diabetes
and renal failure, because of pain, purulent discharge and scar-
ring.1,2 HS is defined clinically by characteristic lesions occur-
ring chronically in flexural locations.3,4 Consensus disease
definitions differ slightly in the chronicity element, ranging
from a history of two to five boils in the axillae or groins.5,6
The prevalence of HS remains controversial, with estimates
ranging from 005% from an analysis of patient insurance
claims in the U.S.A.7 to 4% when young adult women were
examined in person.8 An accurate prevalence figure is required
to quantify the unmet need regarding care of people with HS
to assess disease burden and plan healthcare provision. In par-
ticular, radical surgery or biological therapies are needed for
severe disease that are costly and often require multidisci-
plinary teams; for example, in the U.K., the National Institute
for Health and Care Excellence recently approved adalimumab
for moderate-to-severe HS.9
One explanation for the 80-fold difference in prevalence
estimates currently available is lack of recognition of HS, in
the context that the average diagnostic delay is 7 years.10 The
aim of our study was to provide the most accurate estimate to
date of HS prevalence by quantifying physician-diagnosed
cases, and also unrecognized HS cases meeting the most strin-
gent consensus disease definition for HS. A primary care data
source was chosen because the majority of HS care takes place
within a primary care setting. Our second aim was to assess
HS disease associations with the largest case–control study per-
formed to date. Accurate epidemiological data is critical at a
time when treatment for HS is dramatically changing and now
includes biological therapies.
Patients and methods
Our manuscript was prepared in accordance with RECORD
(Reporting of Studies Conducted using Observational Rou-
tinely-collected Data)11 (for the RECORD checklist see
Appendix S1 in the Supporting Information). The Clinical Prac-
tice Research Datalink (CPRD) contains routinely recorded,
pseudonymized data from participating primary care practices
throughout the U.K.12 Most diagnoses made in secondary care
are transcribed into the CPRD by primary care staff. As of Jan-
uary 2015, it contained records from more than 156 million
patients registered at 684 practices. Patient data are labelled by
the CPRD as being of acceptable research quality if the patient
has been permanently registered at their general practice and
has internally consistent records with regard to age, sex, regis-
tration and event dates. Approximately 75% of contributing
practices based in England (representing 60% of the entire
dataset) participate in a CPRD linkage scheme by which
patient-level data are linked to the hospital episode statistics
(HES) for England. The National Health Service (NHS) num-
ber, date of birth, sex and postal code of nondissenting patients
are conveyed from the practice to a trusted third party and
matched with equivalent identifiers in the target dataset. Only
those linkages involving at least two exact matches, which
must include an exact match on NHS number, are retained.
The study population was selected from patients with data of
acceptable research quality. Physician-diagnosed cases of HS
were captured by two specific diagnostic Read codes, M25y100
(Hidradenitis) and M25y111 (Hidradenitis suppurativa), or, in
HES data, by the International Classification of Disease (ICD)-10
code L732 (Hidradenitis suppurativa). To capture undiagnosed
cases, CPRD Read code algorithms were created to identify
patients attending primary care for multiple skin boil consulta-
tions (Table 1). An algorithm hierarchy was used with different
degrees of stringency for each subalgorithm, based on the HS
disease definition (Fig. 1). Some primary care practitioners may
Table 1 Description of algorithms used to identify proxy hidradenitis
suppurativa cases in the Clinical Practice Research Datalink
Subalgorithm Description
1a ≥ 5 boils, furuncles, carbuncles or abscesses
in flexural skin sites
1b 1–4 boils in flexural sites and ≥ 5 boils in total
1c ≥ 5 boils in unspecified skin sites
2a ‘Multiple boils’ and ≥ 1 flexural boil
2b ‘Multiple boils’ and no flexural lesion specified
3 ‘Drainage or incision of boil of skin’
and ≥ 5 boils in total
4 Surgical excision/laser destruction of flexural skin
5a ≥ 5 short courses of oral flucloxacillin/
erythromycin/clarithromycin and ≥ 1 flexural
boil, excluding eczema/skin ulcer/cellulitis
5b ≥ 5 short courses of oral flucloxacillin/
erythromycin/clarithromycin and ≥ 1 boil in
unspecified skin site, excluding eczema/skin
ulcer/cellulitis
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not record every skin boil consultation, particularly if the patient
also attends with other health issues. To capture these potential
cases, treatment codes were used to identify patients receiving
multiple short courses of skin-directed antibiotic therapy, such
as flucloxacillin, in combination with skin boil Read codes and
in the absence of any other indication for the antibiotic, such as
eczema, cellulitis or skin ulcers. Prior to validation, the cases of
these patients were referred to as ‘proxy cases’. HES data were
not used to identify proxy cases to avoid double-counting boils
recorded in both data sources.
Validation
Validation of proxy cases was carried out by sending question-
naires to the primary care physicians of a subset of patients
identified from the algorithms. The questionnaire (Table 2)
requested confirmation of characteristic skin lesions in flexural
locations on at least five separate occasions, in keeping with
the most stringent consensus definition of the disease.6
A total of 176 questionnaires were sent, with the overall
number being determined by our study budget in the context
that CPRD charges a fee for each questionnaire issued. The
number of questionnaires generated to validate each sub-
algorithm was determined by the number of additional proxy
cases identified through each, with a minimum of 10 ques-
tionnaires being issued for subalgorithms that captured rela-
tively few cases.
Analysis
Point prevalence on 30 June 2013 was calculated using physi-
cian-diagnosed cases and criteria-diagnosed cases as the
numerator and the 2013 mid-year population of live patients
with research-standard records in CPRD as the denominator.
The number of criteria-diagnosed cases was calculated by mul-
tiplying the number of proxy cases identified by each sub-
algorithm with the proportion of cases validated from the
relevant set of GP questionnaires.
Annual incidence rates for physician-diagnosed cases were
calculated from 1988, when up-to-research-standard practices
first contributed to CPRD, until 2013. We used the Brameld–
Holman backcasting method, which implements an actuarial
retrograde survival curve to derive correction factors for the
over-ascertainment of first events for individuals with only a
limited duration of CPRD data collection prior to the event.13
The Brameld–Holman method accounts for the prevalent pool
effect without the need for a clearance period and avoids data
being discarded.
Case–control
Cases and controls were matched in a 1 : 1 ratio based on
age, sex and registration at the same primary care practice.
The associations between HS and environmental factors and
other medical conditions were estimated using conditional
logistic regression techniques. Two separate association analy-
ses were conducted for physician-diagnosed cases compared
with matched controls and for proxy cases (including criteria-
diagnosed HS cases and those proxy cases who did not meet
the validation criteria) compared with a further set of matched
controls. Univariable associations were reported, and also mul-
tivariable analyses that examined combinations of variables
demonstrating association in the univariable analysis with a
Fig 1. Algorithm hierarchy used to capture unrecognized cases of
hidradenitis suppurativa. Schematic representation of subalgorithms
used to detect unrecognized hidradenitis suppurativa with differing
degrees of stringency.
Table 2 Validation questionnaire sent to the primary care physicians
of a subset of proxy hidradenitis suppurativa cases
Question Domain Wording Response
1 Characteristic
lesions
Has your patient
experienced painful,
erythematous papules,
nodules or abscesses
of the skin (boils)?
Yes/no
2 Flexural sites Were these lesions
predominantly located
in flexural skin sites,
specifically the axillae,
groins, buttocks,
perineum and/or
inframammary regions?
Yes/no
3 Chronicity Has your patient
experienced at least five
of these lesions in flexural
skin sites since the age
of 10?
Yes/no
4 Scarring Does your patient have any
‘rope-like’ scars, atrophic
(depressed) scars or sinus
tracts in affected sites?
Yes/no/
unknown
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P-value < 01. In a post hoc analysis we also tested whether
there was evidence that the association between Crohn disease
and HS was altered by smoking status because smoking is
known to be a risk factor for both conditions.
Our study protocol (Appendix S2; see Supporting Informa-
tion), 15_020R, was prospectively approved by the CPRD
Independent Scientific Advisory Committee. No additional
institutional review board approval is required for CPRD
studies.
Results
Point prevalence
On 30 June 2013 there were 21 575 patients with physician-
diagnosed HS in the CPRD dataset and a further 1778 from
the HES dataset; a total of 23 353 individuals with physician-
diagnosed HS. Our Read and treatment code algorithms
captured a further 68 890 proxy cases in the CPRD; the break-
down for each subalgorithm is shown in Table 3. Of the 176
GP validation questionnaires sent, 107 (61%) were fully com-
pleted and returned; completion rates for each subalgorithm
are in Table 3.
The proportions of questionnaires with ‘yes’ responses to
the first three questions, satisfying the most stringent disease
definition of at least five flexural skin boils, are documented
in Table 3; from these, 10 146 criteria-diagnosed cases were
extrapolated. Table 3 also documents the proportions within
each subalgorithm confirmed to have had one to four flexural
boils with ‘yes’ responses to questions one and two only, rep-
resenting a group of probable HS cases. Overall, only one vali-
dation questionnaire confirmed the presence of scarring with
a ‘yes’ answer to question four.
Using the denominator of 4 364 308 research-standard
patients in the CPRD, the prevalence of physician-diagnosed
and criteria-diagnosed HS cases on 30 June 2013 was 77 per
1000 [95% confidence interval (CI) 76–78]. When the
18 417 patients with one to four flexural skin boils were
included, the upper limit of probable HS prevalence was 119
per 1000 (95% CI 118–120).
The demographic profile of patients with physician-diag-
nosed HS is shown in Figure 2. Peak prevalence of 151 per
1000 occurred in the fifth decade of life and the mean
female : male ratio across all the age groups was 29 : 1.
Incidence of physician-diagnosed cases
The Brameld–Holman actuarial retrograde survival curve used
for the backcasting correction for incidence rates is in
Figure S1 (see Supporting Information), with the resulting
correction factors reducing the number of new physician-diag-
nosed cases prior to 1994. The mean annual incidence rate for
physician-diagnosed cases from 1996 to 2013 was 283 per
100 000 person-years (Table S1; see Supporting Information).
Prior to 1995, despite the backcasting correction, annual inci-
dence rates became progressively higher, ranging from 357
per 100 000 person-years in 1995 to 1221 in 1988.
Case–control
Descriptive statistics for the occurrence of environmental fac-
tors and other medical conditions in cases and controls are in
Table 4. Obesity [body mass index (BMI) > 30 kg m2], cur-
rent smoking and type 2 diabetes mellitus were strongly
linked with physician-diagnosed cases of HS, with odds ratios
(ORs) of 329 (95% CI 314–345), 361 (95% CI 344–
379) and 339 (309–371), respectively, in the univariable
analysis (Table 4). There was a significant association between
HS and Crohn disease but not ulcerative colitis. The link with
Crohn disease was not stronger for smokers than nonsmokers
(P = 026 for the interaction test between Crohn disease and
never or past/current smoker). Associations were also found
Table 3 Subalgorithm validation from completed questionnaires returned by primary care practitioners
Subalgorithm
Questionnaires
sent
Questionnaires
completed
Proxy cases
prior to
validation
Proportion
validated with
≥ 5 flexural boils
Extrapolated number
of criteria-diagnosed
casesa
Proportion
validated with
1–4 flexural
boils
Extrapolated
additional
probable casesb
1a 10 6 650 067 435 0 0
1b 10 6 1908 033 629 017 325
1c 10 7 3120 057 1778 029 905
2a 10 3 2083 033 687 034 708
2b 59 38 27 492 013 3573 029 7973
3 0 0 0 0 0 0 0
4 10 5 594 0 0 020 118
5a 14 10 7050 010 705 060 4229
5b 53 32 25 993 009 2339 016 4159
Total 176 107 68 890 10 146 18 417
aCriteria-diagnosed cases are defined as those individuals confirmed by their primary care physician to have a history of at least five flexural
skin boils; badditional probable cases are defined as those individuals confirmed by their primary care physician to have a history of between
one and four flexural skin boils.
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between HS and hyperlipidaemia, pilonidal sinus, acne vul-
garis, depression and hypertension, but not with inflammatory
arthritis, polycystic ovary syndrome, psoriasis or Alzheimer
disease (Table 4). Multivariable analysis confirmed the univari-
able analysis results in all cases (Table S2; see Supporting
Information).
Discussion
Our HS prevalence figure of 077% is derived from a popula-
tion of 43 million U.K. residents with research-standard med-
ical records. Importantly, our study has identified patients
with previously undiagnosed HS using the most stringent
diagnostic criteria available. We have also identified an upper
limit of probable HS prevalence of 119%, if those with a his-
tory of one to four flexural skin boils on separate occasions
are included. This is in the context that patients may not see
their GP for every new skin boil, GPs may not record each
skin boil, particularly if the consultation also covers other
medical issues, and HS disease definitions vary in the number
of flexural skin boils required, from two to five.5,6
Our two prevalence figures span the 097% estimate for
European prevalence derived from a self-reported question-
naire study of 10 000 members of the French population that
Fig 2. Demographics of physician-diagnosed
hidradenitis suppurativa cases. Line graph of
the prevalence rate of physician-diagnosed
hidradenitis suppurativa in U.K. males,
females and in total, subdivided by decade of
age. Superimposed is a histogram of the
female : male ratio for each decade of age.
Prev, prevalence.
Table 4 Case–control study univariable analysisa
Controls, n (%)
Proxy
cases, n (%)
Physician-diagnosed
cases, n (%)
Proxy cases Physician-diagnosed cases
OR (95% CI) P-value OR (95% CI) P-value
Obesity (body mass
index > 30 kg m–2)
19 862 (212) 29 916 (428) 11 145 (464) 277 (270–285) < 0001 329 (314–345) < 0001
Type 2 diabetes
mellitus
4321 (46) 9530 (137) 2158 (90) 332 (318–347) < 0001 339 (309–371) < 0001
Smoking status
Never 48 431 (516) 28 751 (412) 7828 (326) 1 1
Past 12 671 (135) 10 523 (151) 3260 (136) 144 (139–149) < 0001 193 (181–205) < 0001
Current 22 712 (242) 27 748 (397) 12 347 (514) 218 (213–224) < 0001 361 (344–379) < 0001
Crohn disease 187 (02) 310 (04) 122 (05) 221 (181–269) < 0001 265 (189–372) < 0001
Ulcerative colitis 129 (01) 78 (01) 42 (02) 082 (061–111) 02 124 (079–194) 036
Pilonidal sinus 293 (03) 887 (13) 444 (19) 421 (362–489) < 0001 561 (441–712) < 0001
Acne vulgaris 5828 (62) 7858 (113) 2885 (120) 217 (209–227) < 0001 177 (166–188) < 0001
Depression 16 009 (171) 16 968 (243) 6318 (263) 165 (160–169) < 0001 169 (162–177) < 0001
Hyperlipidaemia 2664 (28) 3344 (48) 791 (33) 159 (150–169) < 0001 179 (159–202) < 0001
Hypertension 8090 (86) 8596 (123) 1882 (78) 140 (135–145) < 0001 142 (132–153) < 0001
Inflammatory
arthritis
790 (08) 634 (09) 201 (08) 106 (094–118) 035 106 (087–130) 054
Polycystic
ovary syndrome
377 (04) 252 (04) 181 (08) 112 (094–134) 022 119 (096–149) 011
Psoriasis 879 (09) 671 (10) 247 (10) 103 (092–115) 062 109 (091–131) 033
Alzheimer disease 102 (01) 87 (01) 16 (001) 095 (071–127) 071 160 (073–353) 024
aBased on 93 869 control individuals, 69 842 proxy cases including criteria-diagnosed hidradenitis suppurativa (HS) cases and those who
did not meet the validation criteria, and 24 027 physician-diagnosed cases of HS. Some non-prevalent cases, meeting diagnostic criteria after
30 June 2013, are included. Smoking status was missing from a total of 10 055 records, including 2820 proxy cases and 592 physician-
diagnosed cases and missing data is included in the denominator for calculation of percentages. Body mass index data were missing from
12% of all records and, again, missing data are included in the denominator for calculation of percentages.
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is often cited as the most accurate current estimate.14 In the
French study, cases were identified by positive responses to
one question within a general skin disease survey and the
morphology of skin lesions was not assessed by healthcare
professionals.
One of the largest population-based HS investigations per-
formed prior to our study used data from the Rochester Epi-
demiology Project (REP), which maintains a centralized
electronic medical record database for the 144 000 people liv-
ing in Olmsted County Minnesota, U.S.A.15,16 Identification of
HS cases used codes including synonyms of ‘hidradenitis’,
and also the terms ‘infection, sweat gland or inflammation,
sweat gland’. Validation by chart review identified 178 HS
cases, giving a prevalence of 013%. More recently, interroga-
tion of pooled insurance and self-pay databases covering 48
million people in the U.S.A. using ICD-9 coding for HS gave
a point prevalence of 010%.17 In both studies, identification
of undiagnosed cases by considering multiple flexural skin
boil presentations was not attempted. Part of the explanation
for the lower U.S.A. prevalence figures than in our data is
failure to capture undiagnosed cases. In addition, recognition
and coding of HS by healthcare professionals will vary from
region to region and variations in health systems may influ-
ence whether people with HS persevere with seeking medical
attention for their condition, an issue requiring further
investigation.
Our finding of peak HS prevalence in women in their
fourth and fifth decades of life is in agreement with the
French self-reported questionnaire study, in which the
female : male ratio was 27 : 1 and the mean age of patients
was 432 years.14 Our peak prevalence finding of 151% in
women in their fifth decade is lower than the 4% prevalence
found by examination of a group of female healthcare profes-
sionals and those attending for benign skin lesions in Den-
mark, but the study had a relatively low sample size of 100,
in which there were four cases.8
Our mean annual incidence of physician-diagnosed HS cases
of 283 per 100 000 person-years from 1996 to 2013 is more
than four times higher than the 60 per 100 000 person-years
figure found using REP data for Olmsted County, Minnesota.16
The difference is in keeping with the higher prevalence figure
for physician-diagnosed cases found in our study. The more
recent study of the U.S.A. population using pooled insurance
and self-pay databases found a HS incidence of 114 (95% CI
111–118) per 100 000 population, double the incidence of
the REP-derived estimate.18 Our calculated incidence rates
were much higher in the first few years of available CPRD
data, despite the backcasting correction to negate any preva-
lent pool effect. The observation is likely explained by bulk
computerization of patient paper records during this period,
producing an artefact in this result.
Our case–control study is entirely consistent with other,
smaller studies previously performed. A recent systematic
review of nine relevant studies containing 6174 patients and
24 993 controls confirmed an association between HS and
obesity (OR 345, 95% CI 220–538), in addition to an
association with diabetes (OR 285, 95% CI 134–608), cur-
rent smoking (OR 434, 95% CI 248–760) and past smoking
(OR 634, 95% CI 241–1668).19 Our finding that HS is asso-
ciated with Crohn disease but not ulcerative colitis is in agree-
ment with other studies, including a cross-sectional
investigation of 3267 patients with HS20 and, in addition, we
showed that the association between HS and Crohn disease is
not modified by smoking status. The higher rates of smoking,
type 2 diabetes mellitus, hypertension and hyperlipidaemia
confirmed by our study are in keeping with the nearly dou-
bled risk of cardiovascular-associated death in Danish patients
with HS compared with controls (adjusted incidence rate ratio
195, 95% CI 142–267).21
The strongest association demonstrated by our case–control
study was between HS and pilonidal sinus, with an odds ratio
of 561. The result is expected because both conditions are
members of the ‘follicular occlusion tetrad’ and there is ongo-
ing debate about whether pilonidal sinus may be a phenotypic
variant of HS. We confirmed a link between HS and depres-
sion, with an odds ratio of 155, which is in keeping with a
chronic, painful and socially isolating disease and in agree-
ment with a study of psychiatric comorbidities in 3207
patients with HS (adjusted OR for depression 17, 95% CI
13–21).22 However, we did not assess the timing of disease
associations in our study and so cannot comment further on
possible causation.
Debate continues regarding a possible link between HS and
inflammatory arthritis. A syndrome known as PAPASH (pyo-
derma gangrenosum, acne, psoriasis, arthritis and suppurative
hidradenitis) has been proposed but we did not find evidence
of an association between HS and inflammatory arthritis or
psoriasis.23 Our finding of no link between HS and polycystic
ovary syndrome disagrees with a case–control study based on
2292 patients in the U.S.A. with at least one billing code for
HS, which found an odds ratio of 137 (95% CI 400–
473).24 However, the study found a HS prevalence of only
008%, reflecting limited case-capture from billing codes, and
so case ascertainment bias may have affected the results. We
specifically checked for any link between HS and Alzheimer
disease because of reports of loss of function gamma secretase
gene mutations in some Han Chinese patients with HS and a
small proportion of European families with HS.25,26 Missense
gamma secretase gene mutations are implicated in familial
Alzheimer disease.27 We found no association between HS
and Alzheimer disease, in agreement with a recent case–
control study from Denmark,28 although it is possible that our
relatively young cohort of patients might subsequently
develop dementia later in life.
Considering our study limitations, some relevant data is
missing within the CPRD and it is likely that these will not be
missing at random because patients who are cases are likely to
have greater completeness because of their condition, increas-
ing GP contacts and providing more opportunity for the data
items to be recorded. Coding imperfections may affect results,
mitigated by our validation of undiagnosed cases using the GP
questionnaire. Study budget limitations, rather than statistical
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considerations, restricted the number of validation question-
naires that were sent and so a sampling error is possible.
We did not validate physician-diagnosed HS cases because
false positives are unlikely in the context that HS is a clinically
diagnosed, characteristic skin disease with a low chance of
being confused with other skin conditions. Review of medical
records for patients who had received at least two ICD-9
70583 codes for ‘hidradenitis’ in the Massachusetts General
Hospital database was previously conducted, in the context
that the 70583 code includes neutrophilic eccrine hidradeni-
tis, and recurrent palmoplantar hidradenitis, in addition to
HS.29 Confirmation of HS was obtained in 896% of cases,
while inclusion of the terms ‘hidradenitis’ or ‘HS’ in the med-
ical record gave positive predictive values of 996% (95% CI
989–999%) and 100% (95% CI 958–100%), respectively,
for identification of chart-verified HS. To minimize any risk of
false positives we used only the Read codes for ‘hidradenitis’
and ‘hidradenitis suppurativa’ in our search for physician-
diagnosed cases in the CPRD and used the specific ICD-10
code for ‘hidradenitis suppurativa’, L732, when searching the
HES data.
Validation in person would have been ideal but is not pos-
sible within the ethical parameters of the CPRD. Validation
using a GP questionnaire to check for the consensus definition
of five flexural skin boils would be prone to false negatives.
This is because five skin boil consultations may not be
recorded as separate entries in the medical record in those
with a known diagnosis. For the same reason, we did not
analyse the performance of our algorithms in detecting physi-
cian-diagnosed cases. Descriptive statistics comparing controls
with proxy cases and diagnosed cases support a conclusion
that the proxy group contains mainly patients with HS and
also some individuals who do not have HS, whereas the
physician-diagnosed HS group is representative of a HS popu-
lation. For example, smoking is a known HS risk factor and
our physician-diagnosed group contained 51% active smokers,
compared with 40% in the proxy group and 24% in controls.
In conclusion, analysis of the 43 million U.K. people with
research-standard medical records in the CPRD has permitted
the most comprehensive estimate of HS prevalence so far
obtained, identifying individuals with physician-diagnosed
and criteria-diagnosed cases in primary care. Prevalence of
HS in the U.K. is 077% using the most stringent validation
criteria of five flexural skin boils, rising to a maximum pos-
sible prevalence of 119% if patients with a history of one
to four flexural skin boils are included. Our results demon-
strate that HS is a common condition, highlighting the rela-
tive lack of HS clinical trial evidence to date. For example,
the recent HS Cochrane review included only 12 randomized
controlled trials, involving only 615 participants, one-seventh
of the number of trials and participants included in the
updated Cochrane review of vitiligo, a condition with a sim-
ilar prevalence.30,31 Availability of an accurate prevalence fig-
ure is one of the key foundations to drive further research
in the field of HS.
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